Morgan Stanley's Optimism: The broker is optimistic about the IP industry in China's internet and media sectors, particularly favoring live streaming, games, long-form videos, and movies.
DAMAI ENT's Growth Potential: Morgan Stanley has a positive outlook on DAMAI ENT (01060.HK), raising its target price from HKD0.58 to HKD1.2 due to its strong IP recognition and comprehensive capabilities.
MAOYAN ENT's Downgrade: The film industry is experiencing sluggish growth, leading Morgan Stanley to downgrade MAOYAN ENT (01896.HK) to Equalweight while increasing its target price from HKD7.5 to HKD8.
Short Selling Data: As of October 20, 2025, DAMAI ENT has a short selling ratio of 13.563% with $13.75M in short selling, while MAOYAN ENT has a ratio of 10.758% with $889.09K in short selling.
Wall Street analysts forecast 01060 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01060 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 01060 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01060 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 0.920
Low
Averages
High
Current: 0.920
Low
Averages
High
Goldman Sachs
Goldman Sachs
Buy
maintain
Al Analysis
2025-11-19
Reason
Goldman Sachs
Goldman Sachs
Price Target
Al Analysis
2025-11-19
maintain
Buy
Reason
The analyst rating from Goldman Sachs is maintained as a "Buy" despite a reduction in the target price from HKD 1.3 to HKD 1.17. The reasoning behind this rating includes the solid results reported by DAMAI ENT for 1HFY26 and the expectation that the company's expansion of licensing resources, particularly from Sanrio into retail and consumer markets, will drive strong growth in the next 6-12 months. However, concerns about the slowdown in the domestic ticketing business, increased investments in international markets, and the company's reliance on Japanese intellectual property amid Sino-Japanese tensions have contributed to stock price volatility.
Citi
maintain
2025-11-18
Reason
Citi
Price Target
2025-11-18
maintain
Reason
The analyst rating from Citi is based on the assessment that the delay of the two Japanese films will have a very limited negative impact on China's overall box office, as Japanese films contributed only 5% to the box office last year. The primary concern is related to market sentiment and investor worries about potential risks to MAOYAN ENT, particularly regarding the possible suspension of its key film "Demon Slayer" if geopolitical tensions escalate. Despite the negative sentiment surrounding the involvement of Japanese IP, the actual impact on DAMAI ENT is expected to be minimal. Consequently, Citi has set target prices for DAMAI ENT at HKD1.4 and for MAOYAN ENT at HKD9.3.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01060
Unlock Now
Jefferies
Jefferies
maintain
$1.4
2025-11-07
Reason
Jefferies
Jefferies
Price Target
$1.4
2025-11-07
maintain
Reason
The analyst rating for DAMAI ENT (01060.HK) is maintained at "Buy" with a target price of HKD1.4 due to a positive profit alert for 1HFY26, where estimated earnings are expected to exceed RMB500 million, surpassing both market and Jefferies' forecasts. This growth is attributed to the strong performance of Alifish and a year-over-year reduction in investment losses, aided by an improved asset structure. Additionally, Jefferies anticipates that investment losses will decrease in 1HFY26, contributing to the better-than-expected results.
CICC
CICC
Buy
maintain
$1.32
2025-11-07
Reason
CICC
CICC
Price Target
$1.32
2025-11-07
maintain
Buy
Reason
The analyst rating for DAMAI ENT (01060.HK) is positive due to the company's issuance of a profit alert indicating a significant expected increase in net profit for 1HFY2026, projected to be no less than RMB500 million, which represents a year-on-year growth of approximately 48%. This positive outlook is attributed to the strong performance of the Alifish business, which has shown robust revenue and profit growth. Additionally, the presence of popular intellectual properties (IPs) such as Sanrio, Chiikawa, and Crayon Shin-chan is seen as a key driver of current revenue and profit. CICC has maintained its full-year revenue and profit forecasts for the company and has set a target price that implies a 40% upside from the current stock price, further supporting the positive rating.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
